Ενημέρωση της Roche/ Genentech σχετικά με τη μελέτη GENERATION HD2

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]
Η Novartis τερματίζει τη μελέτη VIBRANT-HD

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]
Η uniQure ανακοίνωσε ότι συνεχίζει την εγγραφή ασθενών στο επίπεδο υψηλότερης δόσης στη δοκιμή AMT-130

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]
Η Wave Life Sciences ανακοινώνει θετική ενημέρωση από τη δοκιμή φάσης 1b/2a SELECT-HD με αρχικά αποτελέσματα που υποδεικνύουν την επιλεκτική δέσμευση στόχων με το WVE-003 στη νόσο του Huntington

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]
Η uniQure ανακοινώνει ενημέρωση για την κοόρτη χαμηλών δόσεων στην κλινική δοκιμή φάσης Ι/ΙΙΙ της γονιδιακής θεραπείας AMT-130 για τη θεραπεία της νόσου του Huntington

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]
Η Annexon Biosciences επικαιροποιεί τα αποτελέσματα των δοκιμών

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]
Webinar - Όλα όσα πρέπει να ξέρετε για το Proof-HD

Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin, […]
Έκτακτη είδηση - Η Roche σχεδιάζει νέα μελέτη Tominersen

Some encouraging news has just come in from Roche. Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]